The University of Southern California (USC) and the City of Hope National Medical Center (COH) have made a significant commitment to Phase I trials of new anticancer drugs. Preclinical and clinical investigators have exchanged views and shared resources on a wide range of activities relevant to such trials; biochemical modulation of halopyrimidines, folate biochemistry and drug development, locoregional therapy, dose- intensification of chemotherapy, reversal of multidrug resistance, modulation of platinum action, bioreductive activation of antitumor quinones, topoisomerase-interacting drugs, and emerging targets related to the biology of differentiation, tumor angiogenesis and metastases. We now have the opportunity to establish a formal collaborative relationship supported by a joint pharmacokinetic core facility, and to work more closely with the National Cancer Institute's drug development programs. These collaborations will enhance our capability to perform Phase I molecular pharmacodynamic trials focused by the pharmacologic expertise available at both institutions. Areas of known strength available to support Phase I studies include our long-standing experience in the pharmacokinetics and pharmacodynamics of fluoropyrimidines and other nucleoside antimetabolites, expertise in the mechanism of action of the anticancer quinones and platinum analogs, and in modeling pharmacokinetic/pharmacodynamic relationships, pioneering experience in the quantitation of relative gene expression from small amounts of tissue, and the availability of reliable data management and biostatistical facilities.
Showing the most recent 10 out of 83 publications
